These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 6132447)

  • 21. Depot fluphenazine: risk/benefit ratio.
    Glazer WM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Adv Biochem Psychopharmacol; 1983; 37():299-308. PubMed ID: 6138952
    [No Abstract]   [Full Text] [Related]  

  • 23. Intermittent neuroleptic therapy and tardive dyskinesia: a literature review.
    Goldman MB; Luchins DJ
    Hosp Community Psychiatry; 1984 Dec; 35(12):1215-9. PubMed ID: 6150891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depot injections and tardive dyskinesia.
    Gibson AC
    Br J Psychiatry; 1978 Oct; 133():361-5. PubMed ID: 709010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia presenting as gastrointestinal disorder.
    Goldberg RJ; Morris PL; Lidofsky S
    J Clin Psychiatry; 1990 Jun; 51(6):253-4. PubMed ID: 1971823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.
    Konitsiotis S; Tsironis C; Kiortsis DN; Evangelou A
    Psychopharmacology (Berl); 2006 Apr; 185(3):369-77. PubMed ID: 16518645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tardive dystonia: a rare side effect after long-term neuroleptic treatment].
    Bartels M; Riffel B; Stöhr M
    Nervenarzt; 1982 Nov; 53(11):674-6. PubMed ID: 6129578
    [No Abstract]   [Full Text] [Related]  

  • 29. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia.
    Diamond BI; Borison RL
    Psychopharmacol Bull; 1986; 22(3):900-5. PubMed ID: 2879312
    [No Abstract]   [Full Text] [Related]  

  • 30. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia: are first signs reversible?
    Quitkin F; Rifkin A; Gochfeld L; Klein DF
    Am J Psychiatry; 1977 Jan; 134(1):84-7. PubMed ID: 12666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.
    Sayers AC; Bürki HR; Ruch W; Asper H
    Psychopharmacology (Berl); 1976 Dec; 51(1):15-22. PubMed ID: 13446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia and the behavioral consequences of chronic neuroleptic treatment.
    Gualtieri CT; Guimond M
    Dev Med Child Neurol; 1981 Apr; 23(2):255-9. PubMed ID: 6111511
    [No Abstract]   [Full Text] [Related]  

  • 36. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia.
    Gunne LM; Bárány S
    Psychopharmacology (Berl); 1979 Jun; 63(3):195-8. PubMed ID: 39307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of chronic neuroleptic administration on cerebral dopamine receptor function.
    Rupniak MN; Jenner P; Marsden CD
    Life Sci; 1983 May; 32(20):2289-311. PubMed ID: 6133203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluphenazine decanoate and tardive dyskinesia.
    Schiff AA
    Am J Psychiatry; 1982 Jul; 139(7):969-70. PubMed ID: 6124136
    [No Abstract]   [Full Text] [Related]  

  • 39. Tardive dyskinesia, fluphenazine decanoate, and haloperidol.
    Waddington JL
    Am J Psychiatry; 1982 May; 139(5):703-4. PubMed ID: 7072867
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.